Most people think of glucagon-like peptide-1 (GLP-1) receptor agonists as tools for blood sugar or body weight research. But a growing body of preclinical and observational work has pointed toward something else: these peptides may also influence how the brain responds to alcohol. A recently published phase 2 randomized clinical trial set out to test that idea directly, enrolling adults who were actively seeking treatment for alcohol use disorder and measuring what happened when they took an oral GLP-1 receptor agonist for eight weeks.
The trial, published in The American Journal of Psychiatry, was double-blind and placebo-controlled, meaning neither participants nor researchers knew who received the active peptide until the data were unblinded. That design is considered a high-quality standard for evaluating whether a compound genuinely produces an effect. Fifty participants with moderate to severe alcohol use disorder were randomly assigned to one of two groups: the peptide or a placebo.
The results were nuanced. Some of the primary outcomes did not reach statistical significance, but several secondary and exploratory measures did, giving researchers reason to call for continued investigation into this peptide class for alcohol-related conditions.
Study design and dosing
Participants received either the oral GLP-1 receptor agonist or a placebo daily for eight weeks. The peptide was given at 3 mg per day for the first four weeks, then stepped up to 7 mg per day for the final four weeks. This gradual escalation mirrors the approach used in many peptide studies to allow the body to adjust and to minimize gastrointestinal side effects that are common with this class.
All fifty participants had moderate to severe alcohol use disorder, which placed them at the more clinically significant end of the diagnostic spectrum. Researchers tracked multiple outcomes simultaneously, including lab-based craving tests, real-world drinking behavior reported by participants, and standardized scales for alcohol-related consequences.
Primary outcome: lab-based craving
The main outcome the trial was powered to detect was alcohol cue-elicited craving measured in a laboratory setting at week six. In that test, participants are exposed to cues associated with alcohol, and their self-reported urge to drink is recorded under controlled conditions. The peptide group did not show a statistically significant reduction on this measure compared with placebo.
Similarly, the total number of drinks per day across the full treatment period did not differ significantly between groups. Missing a primary endpoint in a small phase 2 trial is not unusual. These trials are typically designed to detect signals and estimate effect sizes rather than to deliver definitive proof, and the sample size of fifty participants limits statistical power.
Secondary outcomes that did reach significance
Despite the mixed primary results, several preregistered secondary outcomes moved in a meaningful direction. Heavy drinking days, defined by standard clinical thresholds, were significantly reduced in the peptide group compared with placebo. The statistical estimate showed roughly half a heavy drinking day fewer per week, with a confidence interval that did not cross zero.
Drinks per drinking day also decreased significantly in the peptide group, by a little more than one drink per drinking occasion on average. Naturalistic alcohol craving, meaning the craving people reported in everyday life rather than in a lab setting, was also significantly lower for the peptide group. Researchers note this distinction matters: lab-based craving tests capture a specific, cue-driven moment, while naturalistic craving reflects what people experience across their daily lives.
Alcohol-related negative consequences, measured by a validated scale that captures social, legal, health, and interpersonal problems linked to drinking, decreased at a significantly faster rate in the peptide group. More participants in that group also shifted their World Health Organization risk drinking category downward by at least one level, meaning they moved from a higher-risk to a lower-risk drinking pattern. That categorical shift is considered clinically meaningful in alcohol research.
An unexpected finding on cannabis use
One exploratory result drew particular attention. The peptide group showed a statistically significant reduction in cannabis use days compared with placebo. This was not a primary focus of the trial, so the finding should be interpreted with caution, but it is consistent with preclinical research suggesting that GLP-1 receptor signaling may broadly influence reward-seeking and substance-related behavior rather than being specific to alcohol.
The literature suggests that GLP-1 receptors are expressed in brain regions involved in dopamine signaling and reward processing, including the nucleus accumbens and the ventral tegmental area. If those pathways are modulated by GLP-1 receptor agonist peptides, it would be plausible for effects to extend across different substances. Researchers noted this as a hypothesis worth pursuing in future, larger studies.
What GLP-1 receptors do in the brain
To understand why a metabolic peptide might affect drinking behavior, it helps to know that GLP-1 receptors are not limited to the gut and pancreas. They are present throughout the central nervous system. When activated, they influence dopamine release and the brain's response to rewarding stimuli, including food, alcohol, and other substances.
Preclinical animal studies have shown that GLP-1 receptor agonists reduce voluntary alcohol intake in rodent models. Observational data in humans, including analyses of people who received GLP-1 receptor agonists for other purposes, suggested lower rates of alcohol-related hospitalizations and reduced self-reported drinking. This trial was designed to move beyond those indirect observations and apply a controlled experimental test directly in people with a clinical diagnosis of alcohol use disorder.
Limitations and next steps
The authors were transparent about several limitations. The sample of fifty participants is small, and the trial lasted only eight weeks. Alcohol use disorder is a chronic condition, so a two-month window may not capture long-term effects or durability of any benefit. The dose tested, up to 7 mg per day, is also at the lower end of the range used in other GLP-1 peptide research, meaning higher doses might produce different results.
The trial also enrolled treatment-seeking adults, which is a specific population. Earlier observational work involved people who were not specifically seeking help for drinking. The authors say their findings confirm and extend those earlier signals and conclude that continued development of this peptide for alcohol use disorder is warranted. Larger trials with longer follow-up and potentially higher doses are the logical next step according to the research team.
